Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors

A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients

(2021) Elisabetta Rossi et al.   Translational Lung Cancer Research

Emulating control arms for cancer clinical trials using external cohorts created from electronic health record‐derived real world data

(2021) Katherine Tan et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The use of nonrandomized evidence to estimate treatment effects in health technology assessment

(2021) Seamus Kent et al.   Journal of Comparative Effectiveness Research

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?

(2021) Michael Patrick Lux et al.   Cancer Management and Research

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019

(2020) Emerson Y. Chen et al.   JAMA Internal Medicine

Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes

(2020) John C O’Donnell et al.   Future Oncology

Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU—actions for stakeholders

(2020) Karen M. Facey et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Using electronic health record data to identify comparator populations for comparative effectiveness research

(2020) Scott D. Ramsey et al.   JOURNAL OF MEDICAL ECONOMICS

Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients

(2020) Haiyan E. Liu et al.   Frontiers in Oncology

Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States

(2020) Lisa M Hess et al.   CURRENT MEDICAL RESEARCH AND OPINION

Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in clinical trials of patients with non-small cell lung cancer

(2019) G M Blumenthal et al.   ANNALS OF ONCOLOGY

Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer

(2019) Sandra D. Griffith et al.   ADVANCES IN THERAPY

Selection of Endpoints in Clinical Trials: Trends in European Marketing Authorization Practice in Oncological Indications

(2019) Anna Kordecka et al.   VALUE IN HEALTH

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

(2018) Benjamin J. Solomon et al.   JOURNAL OF CLINICAL ONCOLOGY

A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics

(2018) Julia A. Beaver et al.   JAMA Oncology

Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials.

(2018) Yutao Gong et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

(2017) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework

(2017) Darius N. Lakdawalla et al.   VALUE IN HEALTH

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

(2017) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders

(2017) Tara Nazareth et al.   Journal of Managed Care & Specialty Pharmacy

Use of Electronic Health Record Data for Quality Reporting

(2017) Amy P. Abernethy et al.   Journal of Oncology Practice

1273POVERALL SURVIVAL ANALYSES OF FIRST-LINE ERLOTINIB VERSUS CHEMOTHERAPY IN THE EURTAC STUDY POPULATION CONTROLLING FOR THE USE OF POST-STUDY THERAPY

(2017) L.F. Leon et al.   ANNALS OF ONCOLOGY

Maintenance Chemotherapy in Non–Small Cell Lung Cancer

(2017) Keith D. Eaton et al.   Journal of the National Comprehensive Cancer Network

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

(2015) C. Zhou et al.   ANNALS OF ONCOLOGY

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study

(2015) Denis Moro-Sibilot et al.   LUNG CANCER

Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population

(2015) Luis Lizan et al.   Patient Preference and Adherence

Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non–Small-Cell Lung Cancer

(2015) Darius N. Lakdawalla et al.   JAMA Oncology

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib

(2014) Ingolf Griebsch et al.   BMJ Open

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Limitation of Inverse Probability-of-Censoring Weights in Estimating Survival in the Presence of Strong Selection Bias

(2011) Chanelle J. Howe et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Matching Methods for Causal Inference: A Review and a Look Forward

(2010) Elizabeth A. Stuart   STATISTICAL SCIENCE